Leqvio vs Repatha: Key Differences and How Doctors Tell Them Apart

Leqvio and Repatha are prescription injectable medicines used to lower LDL (“bad”) cholesterol when lifestyle measures and statins alone do not achieve an individual’s treatment goal. Both affect the PCSK9 pathway, but Leqvio reduces PCSK9 production with infrequent clinic-administered doses, while Repatha blocks circulating PCSK9 and is usually self-injected more often.

Leqvio vs Repatha at a glance

Leqvio and Repatha are injectable LDL-cholesterol-lowering medicines. They may be considered for people whose LDL cholesterol remains above the target agreed with their clinician despite lifestyle changes and maximally tolerated statin therapy, or for selected people who cannot take adequate statin treatment. The best option depends on the person’s diagnosis, cardiovascular risk, treatment history and preferences.

Although both treatments act on the PCSK9 pathway, they do so in different ways. This difference affects how often they are given, who administers them, how their effects are maintained and the clinical evidence used when deciding on treatment.

• Feature | Leqvio (inclisiran) | Repatha (evolocumab)
• Medicine type | Small interfering RNA (siRNA) | Monoclonal antibody
• How it works | Reduces the liver’s production of PCSK9 | Binds to and blocks PCSK9 in the bloodstream
• How it is given | Injection under the skin by a healthcare professional | Injection under the skin, commonly self-administered after training
• Usual maintenance schedule | Every six months after initial doses | Every two weeks or once monthly, depending on the prescribed regimen
• Commonly reported effects | Injection-site reactions, joint pain or cold-like symptoms may occur | Injection-site reactions, cold-like symptoms, back or muscle pain may occur
• Important practical distinction | Fewer treatment visits after the starting phase | More frequent dosing but may be managed at home

Exact indications and availability vary by country and may change over time. A prescribing clinician will use local product information and guideline recommendations when determining whether either medicine is appropriate.

How the medicines work differently

LDL cholesterol can build up in artery walls over time and contribute to atherosclerosis, a process linked with heart attack and stroke. The liver uses LDL receptors to remove LDL cholesterol from the blood. PCSK9 is a protein that can reduce the number of available LDL receptors, making it harder for the body to clear LDL cholesterol.

Leqvio contains inclisiran, an siRNA therapy. It works mainly in liver cells by directing the body to make less PCSK9. With less PCSK9 produced, more LDL receptors can remain available to remove LDL cholesterol from the bloodstream. Its long-lasting effect allows maintenance treatment at six-month intervals after the early doses.

Repatha contains evolocumab, a monoclonal antibody. Rather than reducing PCSK9 production, it attaches to PCSK9 that is already circulating and prevents it from interfering with LDL receptors. This results in more LDL receptors being available, but the medicine needs to be given more frequently to sustain this effect.

Both medicines can lower LDL cholesterol substantially when used appropriately. However, the choice is not based only on the expected LDL reduction. Clinicians also consider the person’s overall risk of cardiovascular events, other lipid conditions, ability to follow the dosing plan and the evidence supporting each treatment in a particular clinical setting.

How a clinician tells Leqvio and Repatha apart

The first step is confirming why LDL cholesterol remains high. A clinician reviews fasting or non-fasting lipid measurements, the person’s cardiovascular history, family history, current medicines and adherence to treatment. They may also check for potentially reversible contributors, such as hypothyroidism, kidney disease, liver disease, diabetes or medicines that can affect lipid levels.

Repatha has established use in several high-risk situations, including certain adults with clinical atherosclerotic cardiovascular disease and people with familial hypercholesterolemia, depending on local approval. Familial hypercholesterolemia is an inherited condition that can cause markedly elevated LDL cholesterol from an early age. Learn more about familial hypercholesterolemia.

Leqvio may be considered for adults with elevated LDL cholesterol in specified high-risk settings, often as an addition to diet and statin therapy or other lipid-lowering treatment. A clinician checks whether the individual meets the approved indication in their country and whether the planned clinic-based schedule is practical. Long-term outcome evidence and regulatory indications should be discussed in the context of the individual’s health needs.

The clinician also asks practical questions. Would a six-monthly administered medicine make it easier to stay on treatment? Is a person comfortable with learning self-injection and maintaining a two-weekly or monthly schedule? Is there a history of missed medicines, difficulty attending appointments, needle concerns or reactions to prior injections? These issues do not determine treatment alone, but they can strongly affect whether a plan is realistic and effective.

What to do in common treatment situations

If LDL cholesterol remains high on a statin: The clinician may first confirm that the statin dose is maximally tolerated and assess whether another oral medicine, such as ezetimibe, is appropriate. If additional LDL lowering is needed, Leqvio or Repatha may be considered according to the person’s risk category, diagnosis and local treatment guidance. Treatment is usually continued alongside, rather than instead of, tolerated statin therapy.

If statins cause side effects or cannot be used adequately: Muscle symptoms and other concerns should be reviewed carefully, because symptoms may have more than one cause and alternative statin approaches may sometimes be possible. If true intolerance limits therapy, a clinician can discuss non-statin options and decide whether an injectable PCSK9-pathway treatment is suitable. It is important not to stop prescribed medicine without speaking with the prescriber.

If there has been a heart attack, stroke or artery procedure: This history generally places a person at higher cardiovascular risk and often leads to more intensive LDL-lowering goals. The treating team may recommend additional therapy after reviewing lipid results and the full treatment plan. Related conditions such as coronary artery disease require ongoing management of blood pressure, diabetes, smoking and other risk factors as well as cholesterol.

If inherited high cholesterol is suspected: Very high LDL cholesterol, early heart disease in the family or cholesterol problems in close relatives may prompt evaluation for familial hypercholesterolemia. Family screening and specialist assessment can be valuable. The most appropriate medicine may differ according to the type and severity of the inherited condition.

Safety, monitoring and treatment follow-up

Neither Leqvio nor Repatha should be started without a clinical assessment. People should tell their clinician about allergies, pregnancy or plans for pregnancy, breastfeeding, other medicines and any previous reactions to injectable treatments. Product labeling and recommendations may differ between regions, so individual advice from the prescribing team is essential.

Injection-site reactions, such as redness, swelling, pain or tenderness, can occur with either treatment and are often mild. Some people report cold-like symptoms, joint pain, muscle discomfort or back pain. Any severe, persistent or concerning symptoms should be reported promptly. Signs of a serious allergic reaction, such as trouble breathing, swelling of the face or throat, or widespread hives, require urgent medical attention.

Follow-up lipid testing helps the clinician evaluate response and adjust the overall plan. It also provides an opportunity to review medication adherence, injection technique for self-administered treatment, lifestyle goals and possible adverse effects. Cholesterol results should be interpreted over time rather than judged from a single number alone.

People should continue dietary and lifestyle measures even when taking injectable cholesterol therapy. A heart-healthy eating pattern, regular physical activity suited to the person’s health, maintaining a healthy weight where appropriate, avoiding tobacco and managing blood pressure and diabetes all support cardiovascular health.

Making a shared treatment decision

A useful discussion about Leqvio versus Repatha includes the intended LDL cholesterol goal, the reason that goal is important, the expected schedule, where injections will be given and how follow-up will be arranged. The clinician may also explain which other lipid-lowering medicines should continue and what to do if a dose is delayed or missed.

Leqvio may suit someone who prefers a clinician-administered treatment with infrequent maintenance dosing. Repatha may suit someone who is able and willing to use a home injection schedule and whose diagnosis or cardiovascular history aligns with its approved use. These are examples rather than fixed rules; each choice should be individualized.

A referral to a cardiologist, lipid specialist or endocrinologist may be helpful for complex lipid disorders, very high LDL cholesterol, premature cardiovascular disease or uncertainty about medication tolerance. Specialists can also assess whether other factors, including triglycerides, lipoprotein(a) or inherited conditions, need attention.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals evaluate and treat cholesterol disorders and cardiovascular risk for international patients, with care plans based on the individual’s medical needs.

When to seek medical care

Arrange a routine medical appointment if a blood test shows high LDL cholesterol, there is a strong family history of early heart disease, or current cholesterol treatment is causing side effects or is difficult to follow. A clinician can review the result in context and discuss whether lifestyle support, medication changes or specialist referral is appropriate.

Seek urgent medical care for symptoms that may suggest a heart attack or stroke, including chest pressure or pain, shortness of breath, sudden weakness or numbness on one side of the body, sudden trouble speaking, facial drooping, fainting or sudden severe dizziness. These symptoms are not caused by high cholesterol alone, but high cholesterol can contribute to conditions that raise cardiovascular risk.

Contact the prescribing team promptly after an injection if there is a severe or spreading rash, swelling of the lips, tongue or throat, breathing difficulty, faintness or another suspected serious reaction. For less severe injection-site discomfort or questions about a missed dose, the prescribing clinic or pharmacist can provide guidance.

Frequently asked questions

Is Leqvio better than Repatha?

Neither medicine is automatically better for every person. Both can be effective for lowering LDL cholesterol, but they differ in how they work, how often they are given and the situations in which they are approved. A clinician selects treatment based on cardiovascular risk, diagnosis, prior therapy and practical preferences.

What is the main difference between Leqvio and Repatha?

Leqvio reduces the liver’s production of PCSK9 and is given by a healthcare professional, with maintenance doses every six months after the initial schedule. Repatha blocks PCSK9 in the bloodstream and is generally injected every two weeks or monthly. Both treatments help the liver remove more LDL cholesterol from the blood.

Can Leqvio or Repatha replace a statin?

These medicines are often used in addition to maximally tolerated statin therapy, rather than as a replacement. However, some people cannot take enough statin medicine because of intolerance or other clinical reasons. A clinician can determine whether a non-statin treatment plan is appropriate.

How quickly do Leqvio and Repatha lower cholesterol?

Both medicines can begin lowering LDL cholesterol after treatment starts, but timing and the degree of response vary between individuals. Follow-up blood tests are used to assess the effect over time. The prescriber will advise when lipid testing should be repeated.

Can a person switch from Repatha to Leqvio, or the other way around?

A switch may be possible in some circumstances, but it should only be planned by the prescribing clinician. The team will consider the reason for changing, the timing of doses, cholesterol results, side effects and approved use. People should not overlap, stop or change injectable cholesterol medicines on their own.

Do Leqvio and Repatha have the same side effects?

They share some possible effects, particularly injection-site reactions and cold-like symptoms, but their safety information is not identical. Repatha and Leqvio also have different active ingredients and dosing methods. Any new, persistent or concerning symptoms should be discussed with a clinician.

References

• American Heart Association
• European Society of Cardiology
• U.S. Food and Drug Administration
• National Heart, Lung, and Blood Institute
• National Institute for Health and Care Excellence

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.